title: [5 -fluoropyrimidines for treatment of biliary tract cancers].
authors.affiliation: Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital.
authors.forename: Chigusa
authors.initials: C
authors.lastname: Morizane
authors.forename: Takuji
authors.initials: T
authors.lastname: Okusaka
authors.forename: Hideki
authors.initials: H
authors.lastname: Ueno
authors.forename: Masafumi
authors.initials: M
authors.lastname: Ikeda
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000494:pharmacology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D001661:Biliary Tract Neoplasms / Q000188:drug therapy*; D000069287:Capecitabine; D002986:Clinical Trials as Topic; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D004338:Drug Combinations; D005472:Fluorouracil / Q000031:analogs & derivatives; D006801:Humans; D010094:Oxonic Acid / Q000008:administration & dosage; D011725:Pyridines / Q000008:administration & dosage; D011743:Pyrimidines / Q000008:administration & dosage / Q000494:pharmacology; D005641:Tegafur / Q000008:administration & dosage; D014498:Uracil / Q000008:administration & dosage
chemical_list: D000970:Antineoplastic Agents; D004338:Drug Combinations; D011725:Pyridines; D011743:Pyrimidines; D003841:Deoxycytidine; C079198:S 1 (combination); D005641:Tegafur; D014498:Uracil; D010094:Oxonic Acid; C029269:5-fluoropyrimidine; D000069287:Capecitabine; D005472:Fluorouracil